Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers

By Tcheremissine Oleg V   Castro Manuel A   Gardner Dineen R  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 7-14

Informa Healthcare

Access to resources Recommend Favorite

Health Professionals: How Do They Assess New Medicines?

By Cheng Rebecca   Cook Kirsty   Dowman Sarah   Lawn Rebecca   Leary Jemma   Quinn Taryn   Schroder Kim   Smith Nicola   Tordoff June  

Pharmacy World and Science, Vol. 27, Iss. 3, 2005-06 ,pp. : 236-242

Springer Publishing Company

Access to resources Recommend Favorite

Activities to promote quality use of medicines in New Zealand

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 472, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

The New European Regulation on Pediatric Medicines: Regulatory Perspective

By Hawcutt Daniel B.   Smyth Rosalind L.  

Pediatric Drugs, Vol. 10, Iss. 3, 2008-01 ,pp. : 143-146

Adis International

Access to resources Recommend Favorite

Pharmaceutical Expenditure and Therapeutic Value of New Medicines in Spain

By Darba J.  

PharmacoEconomics, Vol. 21, Iss. 16, 2003-01 ,pp. : 1211-1212

Adis International

Access to resources Recommend Favorite